Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 11/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26050422 | 0.86 | MEN1 (0.36) | MAPTMEN1CYP1A2POLBCYP2D6 | |
| SCHEMBL26049721 | 0.86 | MAPT (0.37) | MAPTMEN1CYP1A2POLBCYP2D6 | |
| SCHEMBL17194951 | 0.79 | PDE2A (0.48) | MEN1CYP1A2POLBKMT2ASMN1; SMN2 | |
| SCHEMBL17194885 | 0.76 | MAPT (0.50) | MAPTMEN1CYP1A2POLBCYP2D6 | |
| SCHEMBL12579013 | 0.75 | HSD17B10 (0.45) | HMGCRHSD17B10KDM4E | |
| SCHEMBL12701526 | 0.75 | PDE2A (0.48) | MAPTMEN1CYP1A2POLBCYP2D6 | |
| SCHEMBL13248471 | 0.74 | HMGCR (0.36) | HMGCRSMN1; SMN2HSD17B10PDE2A | |
| SCHEMBL9120337 | 0.73 | NOS2 (0.38) | MAPTMEN1CYP1A2POLBCYP2D6 | |
| SCHEMBL10220478 | 0.72 | ALDH1A1 (0.36) | HMGCR | |
| SCHEMBL24359766 | 0.70 | MEN1 (0.38) | MAPTMEN1CYP1A2POLBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200071315-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2020-03-05 | — | — | US | disclosed |
| US-10000480-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000480-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170022192-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-26 | — | — | US | disclosed |
| US-20170022192-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2017-01-26 | — | — | US | disclosed |
| US-9505748-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150299183-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000480-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | IFNG, IFNAR1, TYK2 | HMGCR 3834/4885MAPT 3440/4885MEN1 3673/4885 |
| US-20150299183-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | HMGCR 3834/4885MAPT 3440/4885MEN1 3673/4885 |
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | IFNG, IFNAR1, TYK2 | HMGCR 3834/4885MAPT 3440/4885MEN1 3673/4885 |
| US-20170022192-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | HMGCR 3834/4885MAPT 3440/4885MEN1 3673/4885 |
| US-20200071315-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | HMGCR 3834/4885MAPT 3440/4885MEN1 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.